ClinicalTrials.gg
CompletedNCT05622084Updated Oct 22, 2026

The Inperia Advance Post-Market Retrospective Study

An observational study in Peripheral Arterial Disease, sponsored by CID S.p.A.. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CID S.p.A. · Observational

How we know

Updated Oct 22, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
32
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.

Enrollment
50th of 54
32 · median 298
Started
2023
with 5 others
Observational
54 of 120
8 open now
Registered
102nd of 120
by date

Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 50th largest by enrollment of the 54 observational ones that give a count, is one of 6 that started in 2023, is one of 54 observational ones, and was the 102nd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Peripheral Arterial Disease with a site in France, or all of them as a file.
02

Study summary

The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis. The aim of this post-market retrospective study protocl P32203 is to collect clinical data of patients treated with Inperia Advance for the treatment of infra-popliteal artery stenosis in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the device at least 12 months prior to the study start.

Read the detailed description

The objective of this post-market study is to systematically collect retrospective clinical data on the implantable medical device Inperia Advance in the daily clinical practice in an unselected population treated within the intended use. Data will be collected via medical chart review in anonymous form to assess the safety and efficacy of Inperia Adavance. The Inperia Advance Carbostent™ is a CE-marked infra-popliteal stent for treatment of infra-popliteal artery stenosis.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients implanted with at least one Inperia Advance stent for treatment of infra-popliteal artery stenosis, at least 12 months prior to the start date of the retrospective data collection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been implanted with at least one Inperia Advance device according to the indications described in the Instructions for Use (IFU).
  • Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection.

Exclusion criteria

Exclusion Criteria:

  • Patients treated less than 12 months prior to study start
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
32 participants (actual)
Patient registry
No

Interventions

  • DeviceInperia Advance

    Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device

06

What researchers measure

Primary outcomes

  1. Rate of Major Adverse Events (MAE)

    Composite endpoint of all causes of death, unplanned target limb major amputation and/or clinically indicated target lesion revascularization (TLR)

    Time frame: 12 months

Secondary outcomes

  1. Primary patency

    Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) \>2.4 (Duplex Ultrasound evaluation)

    Time frame: 6 months and 12 months

  2. Limb-salvage rate (LSR)

    Limb-salvage rate (LSR) is defined as rate of patients free from major amputation. Major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot

    Time frame: 6 months and 12 months

  3. Secondary patency

    Patency following successful target lesion revascularization (TLR)

    Time frame: 6 months and 12 months or latest patency data available

  4. Death

    Death within 30 days of the index procedure

    Time frame: 30 days

  5. Clinically driven Target Lesion Revascularization

    Clinically driven Target Lesion Revascularization

    Time frame: 6 months and 12 months

  6. Target limb ischemia

    Target limb ischemia requiring surgical intervention or surgical repair of target vessel rate

    Time frame: 6 months and 12 months

  7. Rutherford category measurement

    Rutherford category measurement

    Time frame: pretreatment, 6 months and 12 months

  8. Evaluation of Serious Adverse Events (SAEs)

    Evaluation of Serious Adverse Events (SAEs)

    Time frame: 6 months and 12 months

  9. Acute success (device and procedural) within discharge

    Clinical device success defined as successful delivery and deployment of the stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple stents) and final residual stenosis of the target lesion minor or equal to 30%, assessed by visual estimation and clinical device success without the occurrence of MAE during the hospital stay

    Time frame: 24/72 hours

07

Study locations

1 site
  • CHRU Strasbourg
    Strasbourg, France
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Jun 2023, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2023 → Mar 2023 and completion Jul 2023 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 18, 2022
StartActual
Mar 9, 2023was Feb 2023
Primary completionActual
Jun 2, 2023
CompletionActual
Jun 2, 2023was Jul 2023
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 22, 2026
Start date
Feb 2023→Mar 9, 2023 (actual)
Oct 22, 2026
Study completion
Jul 2023→Jun 2, 2023 (actual)
Oct 22, 2026
Enrollment
50 (estimated)→32 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Completed
    Start date Feb 2023→Mar 9, 2023 (now actual)
    Study completion Jul 2023→Jun 2, 2023 (now actual)
    Enrollment 50 (estimated)→32 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05622084
Lead sponsor
CID S.p.A.
Collaborators
Meditrial Europe Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2022
Start date
Mar 9, 2023
Primary completion
Jun 2, 2023
Completion
Jun 2, 2023
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion